Neurodegenerative Diseases - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 348

Neurodegenerative Diseases – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Neurodegenerative Diseases - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neurodegenerative Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurodegenerative Diseases. Neurodegenerative Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neurodegenerative Diseases.
- A review of the Neurodegenerative Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neurodegenerative Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neurodegenerative Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neurodegenerative Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 7
List of Figures 14
Introduction 15
REPORT COVERAGE 15
Neurodegenerative Diseases Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Neurodegenerative Diseases 17
Neurodegenerative Diseases Therapeutics under Development by Companies 19
Neurodegenerative Diseases Therapeutics under Investigation by Universities/Institutes 36
Late Stage Products 41
Comparative Analysis 41
Mid Clinical Stage Products 42
Comparative Analysis 42
Early Clinical Stage Products 43
Comparative Analysis 43
Discovery and Pre-Clinical Stage Products 44
Comparative Analysis 44
Neurodegenerative Diseases Therapeutics – Products under Development by Companies 45
Neurodegenerative Diseases Therapeutics – Products under Investigation by Universities/Institutes 71
Companies Involved in Neurodegenerative Diseases Therapeutics Development 75
Bristol-Myers Squibb Company 75
Genzyme Corporation 76
Baxter International Inc. 77
Boehringer Ingelheim GmbH 78
F. Hoffmann-La Roche Ltd. 79
Abbott Laboratories 80
Biogen Idec Inc. 81
NsGene A/S 82
Sanofi-Aventis 83
AstraZeneca PLC 84
Eli Lilly and Company 85
GlaxoSmithKline plc 86
Genentech, Inc. 87
Isis Pharmaceuticals, Inc. 88
Apotex, Inc. 89
Merck & Co., Inc. 90
United Biomedical, Inc. 91
Taisho Pharmaceutical Co., Ltd. 92
Euroscreen S.A. 93
Applied NeuroSolutions, Inc. 94
ACE BioSciences A/S 95
Takeda Pharmaceutical Company Limited 96
ExonHit Therapeutics SA 97
Avineuro Pharmaceuticals, Inc. 98
Ipsen S.A. 99
Reliance Life Sciences Pvt. Ltd. 100
Nanotherapeutics, Inc. 101
Senexis Limited 102
Novartis AG 103
Aphios Corporation 104
EnVivo Pharmaceuticals 105
Astellas Pharma Inc. 106
Cephalon, Inc. 107
Chiesi Farmaceutici SpA 108
Daewoong Pharmaceutical Co., Ltd. 109
Eisai Co., Ltd. 110
Elan Corporation, plc 111
H Lundbeck A/S 112
Kowa Company, Ltd. 113
Les Laboratoires Servier 114
Merz GmbH & Co. KGaA 115
Octapharma AG 116
Orion Corporation 117
Pfizer Inc. 118
Toyama Chemical Co. Ltd 119
Vertex Pharmaceuticals Incorporated 120
ViroPharma Incorporated 121
VIVUS, Inc. 122
Hadasit Medical Research Services & Development Ltd 123
BrainStorm Cell Therapeutics Inc. 124
Merck KGaA 125
Addex Pharmaceuticals 126
Evotec Aktiengesellschaft 127
Anavex Life Sciences Corp. 128
Proneuron Biotechnologies, Inc. 129
Neuralstem, Inc. 130
Amicus Therapeutics, Inc. 131
Genfit 132
AVANIR Pharmaceuticals 133
Living Cell Technologies Limited 134
Lpath, Inc. 135
BELLUS Health Inc 136
ReGenX Biosciences, LLC 137
Neuro-Hitech, Inc. 138
NeuroSearch A/S 139
Nymox Pharmaceutical Corporation 140
Osta Biotechnologies Inc. 141
Cortex Pharmaceuticals, Inc. 142
Critical Outcome Technologies Inc. 143
PharmAthene, Inc. 144
ACADIA Pharmaceuticals Inc. 145
Alnylam Pharmaceuticals, Inc 146
ProteoTech, Inc. 147
Yungjin Pharm Ind. Co., Ltd. 148
WhanIn Pharmaceutical Co., Ltd. 149
Repligen Corporation 150
Phytopharm Plc 151
SYGNIS Pharma AG 152
Prana Biotechnology Limited 153
Biotie Therapies Corp. 154
Transition Therapeutics Inc. 155
Allon Therapeutics Inc. 156
Neurim Pharmaceuticals (1991) Ltd. 157
Samaritan Pharmaceuticals, Inc. 158
Theravance, Inc. 159
Suven Life Sciences Ltd. 160
Galapagos NV 161
MediPost Co., Ltd. 162
Summit Corporation plc 163
Proximagen Neuroscience plc. 164
Santhera Pharmaceuticals Holding AG 165
Newron Pharmaceuticals S.p.A. 166
Raptor Pharmaceuticals Corp. 167
Mithridion, Inc. 168
Teikoku Pharma USA, Inc. 169
Xel Pharmaceuticals, Inc. 170
Oryzon 171
TauRx Therapeutics Ltd 172
Ceregene, Inc. 173
CoMentis, Inc. 174
AC Immune SA 175
Humanetics Corporation 176
Noscira, S.A. 177
Accera, Inc. 178
Sonexa Therapeutics, Inc. 179
Bio-Link 180
D-Pharm Ltd. 181
StemCells, Inc. 182
Avanti Therapeutics 183
SCYNEXIS, Inc. 184
Axxam SpA 185
Chipscreen Biosciences Ltd 186
Probiodrug AG 187
Snowdon Inc. 188
Domain Therapeutics 189
Wellstat Therapeutics Corporation 190
Celon Pharma Sp. z o.o. 191
BIOALVO S.A. 192
Aegera Therapeutics Inc. 193
IMMD Inc. 194
AngioChem Inc. 195
CoLucid Pharmaceuticals, Inc. 196
Phoenix Biotechnology, Inc. 197
Metabolic Solutions Development Co. 198
Hawthorn Pharmaceuticals, Inc. 199
Antyra, Inc. 200
TetraLogic Pharmaceuticals 201
BioArctic Neuroscience AB 202
Vaxin, Inc. 203
Indus Biotech Private Limited 204
Affichem 205
Theraptosis S.A. 206
Adamas Pharmaceuticals, Inc. 207
QR Pharma, Inc. 208
NeuroNascent, Inc. 209
Siena Biotech S.p.A. 210
Virobay Inc. 211
SeneXta Therapeutics SA 212
NovaLead Pharma Pvt. Ltd. 213
KineMed, Inc. 214
Intellect Neurosciences, Inc. 215
Omeros Corporation 216
Xencor, Inc. 217
Acetylon Pharmaceuticals, Inc. 218
Adeona Pharmaceuticals, Inc. 219
Intra-Cellular Therapies, Inc. 220
Stemedica Cell Technologies, Inc. 221
Targacept, Inc. 222
N-Gene Research Laboratories, Inc. 223
RemeGenix, Inc. 224
AB Science 225
Vitae Pharmaceuticals, Inc. 226
to-BBB technologies BV 227
Tautatis Incorporated 228
Krenitsky Pharmaceuticals Inc. 229
Lipopharma 230
Medisyn Technologies, Inc. 231
Nexgenix Pharmaceuticals, LLC 232
PALUMED S.A. 233
Proteostasis Therapeutics, Inc. 234
M's Science Corporation 235
NasVax Ltd. 236
BrainCells Inc. 237
Stelic Institute & Co. 238
EndoCeutics, Inc. 239
Vybion, Inc. 240
aFraxis Inc. 241
Pharnext SAS 242
PharmatrophiX, Inc. 243
Satori Pharmaceuticals Inc. 244
Heptares Therapeutics Ltd. 245
Signum Biosciences, Inc. 246
Neuraltus Pharmaceuticals, Inc. 247
ArmaGen Technologies, Inc. 248
RNL BIO Co., Ltd. 249
Ausio Pharmaceuticals, LLC 250
BioChromix Pharma AB 251
Archer Pharmaceuticals, Inc. 252
Varinel, Inc. 253
Cognosci, Inc. 254
Reviva Pharmaceuticals Inc. 255
RaQualia Pharma Inc. 256
Immune Technologies and Medicine 257
Prosensa Therapeutics B.V. 258
Sigmoid Pharma. 259
Naurex, Inc. 260
STATegics, Inc. 261
PharmaNeuroBoost N.V. 262
Chemotherapy Induced Pain – Therapeutics Assessment 263
Assessment by Monotherapy Products 263
Assessment by Combination Products 264
Assessment by Route of Administration 265
Assessment by Molecule Type 267
Drug Profiles 269
solanezumab - Drug Profile 269
donepezil hydrochloride - Drug Profile 271
pridopidine - Drug Profile 273
Vitamin E + Selenium - Drug Profile 275
idebenone - Drug Profile 276
olanzapine - Drug Profile 278
ubidecarenone - Drug Profile 279
thalidomide - Drug Profile 280
SK-PC-B70M - Drug Profile 281
citalopram hydrobromide - Drug Profile 283
Vitamin E + Namenda - Drug Profile 284
Doxycycline + Rifampicin - Drug Profile 286
doxycycline - Drug Profile 287
rifampin - Drug Profile 288
valproic acid - Drug Profile 289
rivastigmine - Drug Profile 290
pioglitazone hydrochloride - Drug Profile 291nilvadipine - Drug Profile 296
rifampin - Drug Profile 298
Intravenous Immunoglobulin - Drug Profile 299
Arimenda - Drug Profile 301
Memantine + Vitamin D3 - Drug Profile 302
pimavanserin tartrate - Drug Profile 303
Femivia - Drug Profile 304
Neurodegenerative Diseases Therapeutics – Drug Profile Updates 305
Neurodegenerative Diseases Therapeutics – Discontinued Products 312
Neurodegenerative Diseases Therapeutics - Dormant Products 319
Chemotherapy Induced Pain – Product Development Milestones 337
Featured News & Press Releases 337
Appendix 345
Methodology 345
Coverage 345
Secondary Research 345
Primary Research 345
Expert Panel Validation 345
Contact Us 346
Disclaimer 346

List of Tables
Number of Products Under Development for Neurodegenerative Diseases, H2 2012 19
Products under Development for Neurodegenerative Diseases – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 40
Comparative Analysis by Late Stage Development, H2 2012 43
Comparative Analysis by Mid Clinical Stage Development, H2 2012 44
Comparative Analysis by Early Clinical Stage Development, H2 2012 45
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 46
Products under Development by Companies, H2 2012 47
Products under Development by Companies, H2 2012 (Contd..1) 48
Products under Investigation by Universities/Institutes, H2 2012 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 74
Bristol-Myers Squibb Company, H2 2012 77
Genzyme Corporation, H2 2012 78
Baxter International Inc., H2 2012 79
Boehringer Ingelheim GmbH, H2 2012 80
F. Hoffmann-La Roche Ltd., H2 2012 81
Abbott Laboratories, H2 2012 82
Biogen Idec Inc., H2 2012 83
NsGene A/S, H2 2012 84
Sanofi-Aventis, H2 2012 85
AstraZeneca PLC, H2 2012 86
Eli Lilly and Company, H2 2012 87
GlaxoSmithKline plc, H2 2012 88
Genentech, Inc., H2 2012 89
Isis Pharmaceuticals, Inc., H2 2012 90
Apotex, Inc., H2 2012 91
Merck & Co., Inc., H2 2012 92
United Biomedical, Inc., H2 2012 93
Taisho Pharmaceutical Co., Ltd., H2 2012 94
Euroscreen S.A., H2 2012 95
Applied NeuroSolutions, Inc., H2 2012 96
ACE BioSciences A/S, H2 2012 97
Takeda Pharmaceutical Company Limited, H2 2012 98
ExonHit Therapeutics SA, H2 2012 99
Avineuro Pharmaceuticals, Inc., H2 2012 100
Ipsen S.A., H2 2012 101
Reliance Life Sciences Pvt. Ltd., H2 2012 102
Nanotherapeutics, Inc., H2 2012 103
Senexis Limited, H2 2012 104
Novartis AG, H2 2012 105
Aphios Corporation, H2 2012 106
EnVivo Pharmaceuticals, H2 2012 107
Astellas Pharma Inc., H2 2012 108
Cephalon, Inc., H2 2012 109
Chiesi Farmaceutici SpA, H2 2012 110
Daewoong Pharmaceutical Co., Ltd., H2 2012 111
Eisai Co., Ltd., H2 2012 112
Elan Corporation, plc, H2 2012 113
H Lundbeck A/S, H2 2012 114
Kowa Company, Ltd., H2 2012 115
Les Laboratoires Servier, H2 2012 116
Merz GmbH & Co. KGaA, H2 2012 117
Octapharma AG, H2 2012 118
Orion Corporation, H2 2012 119
Pfizer Inc., H2 2012 120
Toyama Chemical Co. Ltd, H2 2012 121
Vertex Pharmaceuticals Incorporated, H2 2012 122
ViroPharma Incorporated, H2 2012 123
VIVUS, Inc., H2 2012 124
Hadasit Medical Research Services & Development Ltd, H2 2012 125
BrainStorm Cell Therapeutics Inc., H2 2012 126
Merck KGaA, H2 2012 127
Addex Pharmaceuticals, H2 2012 128
Evotec Aktiengesellschaft, H2 2012 129
Anavex Life Sciences Corp., H2 2012 130
Proneuron Biotechnologies, Inc., H2 2012 131
Neuralstem, Inc., H2 2012 132
Amicus Therapeutics, Inc., H2 2012 133
Genfit, H2 2012 134
AVANIR Pharmaceuticals, H2 2012 135
Living Cell Technologies Limited, H2 2012 136
Lpath, Inc., H2 2012 137
BELLUS Health Inc, H2 2012 138
ReGenX Biosciences, LLC, H2 2012 139
Neuro-Hitech, Inc., H2 2012 140
NeuroSearch A/S, H2 2012 141
Nymox Pharmaceutical Corporation, H2 2012 142
Osta Biotechnologies Inc., H2 2012 143
Cortex Pharmaceuticals, Inc., H2 2012 144
Critical Outcome Technologies Inc., H2 2012 145
PharmAthene, Inc., H2 2012 146
ACADIA Pharmaceuticals Inc., H2 2012 147
Alnylam Pharmaceuticals, Inc, H2 2012 148
ProteoTech, Inc., H2 2012 149
Yungjin Pharm Ind. Co., Ltd., H2 2012 150
WhanIn Pharmaceutical Co., Ltd., H2 2012 151
Repligen Corporation, H2 2012 152
Phytopharm Plc, H2 2012 153
SYGNIS Pharma AG, H2 2012 154
Prana Biotechnology Limited, H2 2012 155
Biotie Therapies Corp., H2 2012 156
Transition Therapeutics Inc., H2 2012 157
Allon Therapeutics Inc., H2 2012 158
Neurim Pharmaceuticals (1991) Ltd., H2 2012 159
Samaritan Pharmaceuticals, Inc., H2 2012 160
Theravance, Inc., H2 2012 161
Suven Life Sciences Ltd., H2 2012 162
Galapagos NV, H2 2012 163
MediPost Co., Ltd., H2 2012 164
Summit Corporation plc, H2 2012 165
Proximagen Neuroscience plc., H2 2012 166
Santhera Pharmaceuticals Holding AG, H2 2012 167
Newron Pharmaceuticals S.p.A., H2 2012 168
Raptor Pharmaceuticals Corp., H2 2012 169
Mithridion, Inc., H2 2012 170
Teikoku Pharma USA, Inc., H2 2012 171
Xel Pharmaceuticals, Inc., H2 2012 172
Oryzon, H2 2012 173
TauRx Therapeutics Ltd, H2 2012 174
Ceregene, Inc., H2 2012 175
CoMentis, Inc., H2 2012 176
AC Immune SA, H2 2012 177
Humanetics Corporation, H2 2012 178
Noscira, S.A., H2 2012 179
Accera, Inc., H2 2012 180
Sonexa Therapeutics, Inc., H2 2012 181
Bio-Link, H2 2012 182
D-Pharm Ltd., H2 2012 183
StemCells, Inc., H2 2012 184
Avanti Therapeutics, H2 2012 185
SCYNEXIS, Inc., H2 2012 186
Axxam SpA, H2 2012 187
Chipscreen Biosciences Ltd, H2 2012 188
Probiodrug AG, H2 2012 189
Snowdon Inc., H2 2012 190
Domain Therapeutics, H2 2012 191
Wellstat Therapeutics Corporation, H2 2012 192
Celon Pharma Sp. z o.o., H2 2012 193

List of Figures
Number of Products under Development for Neurodegenerative Diseases, H2 2012 19
Products under Development for Neurodegenerative Diseases – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 38
Late Stage Products, H2 2012 43
Mid Clinical Stage Products, H2 2012 44
Early Clinical Stage Products, H2 2012 45
Discovery and Pre-Clinical Stage Products, H2 2012 46
Assessment by Monotherapy Products, H2 2012 265
Assessment by Combination Products, H2 2012 266
Assessment by Route of Administration, H2 2012 267
Assessment by Stage and Route of Administration, H2 2012 268
Assessment by Molecule Type, H2 2012 269
Assessment by Stage and Molecule Type, H2 2012 270

Customers who bought this item also bought

• Psoriasis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Schizophrenia - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Hepatitis - Pipeline Review, H2 2012